What one share of Kalaris Therapeutics holds
We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs.
Kalaris Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.07 |
|---|---|
| Cash and investments | $1.81 |
| Book value | $2.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$51.77 | — | — | — | −$71.23 |
| 2025 | — | −$2.85 | $0.01 | −$2.53 | — | $3.44 |
Common questions about Kalaris Therapeutics
How much does one share of Kalaris Therapeutics earn?
Over the last 12 months, Kalaris Therapeutics lost $2.07 for each share.
Does Kalaris Therapeutics pay a dividend?
Kalaris Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Kalaris Therapeutics’s book value per share?
Kalaris Therapeutics’s book value is $2.42 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Kalaris Therapeutics have?
Each share of Kalaris Therapeutics has $1.81 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.